ARADIGM CORP. ARDM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (79)	1/16/2001 12:24:50 PM
From: tuck	Read Replies (1) of 255

biz.yahoo.com >>Aradigm Raises $5 Million Through Put Option in Original Agreement With GlaxoSmithKline HAYWARD, Calif., Jan. 16 /PRNewswire/ -- Aradigm Corporation (Nasdaq: ARDM - news) announced today that the company has raised $5 million through the sale of 339,961 common shares at an average price of $14.71 per share to GlaxoSmithKline. The sale was made pursuant to the exercise of a put option by Aradigm under the terms of its collaboration agreement with GlaxoSmithKline. Under the collaboration, Aradigm is currently conducting a Phase 2b clinical trial for the development of the AERx (R) Pain Management System for the pulmonary delivery of morphine to provide immediate pain relief to patients in the home environment." snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next